Cue Biopharma Inc
CUE
NASDAQ
Biotechnology
$34.20
USD
+3.12 (+10.04%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $131.26M
Volume 156.8K
Revenue
$32.73M
TTM
+309.6%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-19.52M
TTM
+51.9%
YoY
Operating Cash Flow
$-24.46M
TTM
+29.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.4 | 3.0 | 2.1 | 21.9 | 5.7 |
YoY Growth | -75.5% | +11.1% | -35.6% | +1292.3% | +1250.6% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.4 | 3.0 | 2.1 | 21.9 | 5.7 |
Selling, General & Administrative | 4.2 | 3.7 | 4.9 | 3.5 | 4.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | -0.0 |
Total Operating Expenses | 12.7 | 11.6 | 9.7 | 20.0 | 11.0 |
Operating Income | -12.3 | -8.6 | -7.5 | 2.0 | -5.4 |
EBITDA | -12.2 | -8.5 | -7.5 | 2.6 | -4.8 |
Other Income / Expense | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 |
Total Other Income / Expense | 0.0 | 0.2 | 0.1 | 0.1 | 0.2 |
Income Before Income Taxes | -12.3 | -8.5 | -7.4 | 2.1 | -5.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 |
Net Income | -12.3 | -8.5 | -7.4 | 1.6 | -5.2 |
Consolidated Net Income / Loss | -12.3 | -8.5 | -7.4 | 1.6 | -5.2 |
Net Income Attributable to Common Shareholders | -12.3 | -8.5 | -7.4 | 1.6 | -5.2 |
Basic EPS | -$4.95 | -$2.70 | -$2.10 | $0.44 | -$1.08 |
Diluted EPS | -$4.95 | -$2.70 | -$2.10 | $0.44 | -$1.08 |
Basic Shares Outstanding | 2.5M | 3.2M | 3.4M | 3.6M | 4.8M |
Diluted Shares Outstanding | 2.5M | 3.2M | 3.4M | 3.6M | 4.8M |